Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isotechnika Pharma Inc IPHAF

Healthcare Biotechnology


GREY:IPHAF - Post by User

Isotechnika Pharma Inc
Bullboard Posts
User Avatar Image
(0)
•••
Comment by rfk67on Apr 08, 2008 12:49am
237 Views
Post# 14947707

RE: april 7th and counting.....

RE: april 7th and counting....."how long will renal phase III take? start date? how long will psoriasis take? 

basically, when does this drug hit any of it's intended markets? including uveitis, stents, renal, psoriasis, etc...

when will this co. turn from theoretical to real revenues...??? are there any revenue models? are there any eps estimates for once it's on the market?   "

You know anotoninus I used to buy your line about how you were just a disgruntled shareholder who wanted to air his grievances but this post has opened my eyes.
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities